Photo:
Group
photo
at
the
launch
1、
High-end
medical
aesthetics:
GeneQueens
series
At the launch, the Group unveiled the high-end series of 肌顏態® -——GeneQueensTM (Human-Sequence Triple Protein Repair & Balance Ampoule). which functions on skin repair and anti-aging. By activating cell regeneration, it helps users restore their youthful and healthy skin condition.
Photo:
GeneQueens
product
image
GeneQueensTM
sets
a
new
standard
for
anti-aging
and
repair
by
adding
three
core
ingredients
in
sufficient
quantities.
Skbrella
FN,
as
a
key
ingredient
for
cell
repair,
can
accelerate
the
healing
of
skin
wounds
and
promote
the
adhesion
and
migration
of
new
cells.
III
Collagen
strongly
fills
the
skin
structure,
significantly
enhancing
elasticity
and
firmness.
XVII
Collagen
can
strengthen
the
connection
between
the
epidermis
and
dermis,
and
consolidate
the
youthful
foundation
of
the
skin.
In addition, GeneQueens adopts a sterile and preservative-free formula, relying on high-purity raw materials and patented technology, providing users with an “instant enjoyment” precise and efficient experience. Its unique formula and outstanding efficacy were highly recognized by many experts on the spot.
2、金因敷 showcased a variety of new products
Meanwhile, the Group also launched several new products of its medical device brand – 金因敷®, focusing on the professional repair field of medical aesthetics.
Photo:
金因敷
series
product
picture
金因敷®
complies
with
strict
clinical
trials
and
quality
inspections
to
ensure
its
safety
and
effectiveness.
The
product
adopts
a
high-purity
non-allergenic
formula,
which
can
moisturize
and
accelerate
wound
repair.
It
also
uses
an
exclusive
cooling
technology
to
relieve
postoperative
swelling
and
pain,
providing
a
professional
solution
for
sensitive
skin
and
post-medical
procedure
care.
3、The latest research data was presented at CSD2025
It is worth mentioning that 肌顏態® also showcased the research data of “The Efficacy Study of Fibronectin in the Repair of Skin Barrier Damage for the post-medical procedure” jointly conducted with the Cosmetics Testing Center of the Dermatology Hospital of Southern Medical University in the poster area of the 30th Academic Conference of the Chinese Medical Association (CSD2025). This is not only an endorsement of the Group’s research capabilities, but also provides experts and scholars in the industry with an opportunity to gain a deeper understanding of the 肌顏態® technology and products.
As an annual grand event in the field of dermatology and venereology in China, CSD2025 brings together authoritative experts and scholars in dermatology across the country, presenting multi-dimensional academic achievements and exchanges of ideas. The poster area is one of the core venues of the academic annual conference. Posters are not only an important way for researchers to showcase their scientific research achievements, but also a key link in promoting the dissemination of academic ideas and the feedback of clinical practice.
Photo:
The
research
poster
of
肌顏態
at
the
CSD
2025
4、Academic
speeches
by
several
experts
Several clinical experts at the launch further recognized the significant clinical value of 肌顏態® and 金因敷®. The experts highlighted that 肌顏態®‘ s patented ingredient, Skbrella FN, demonstrates immense potential in improving damaged sensitive skin barriers, reducing inflammatory erythema, alleviating discomfort sensations such as burning, tightness and itching, as well as enhancing post-laser repair and healing.
In the clinical observations over the past few months, many patients treated with 肌顏態® have achieved remarkable therapeutic effects. The symptoms of anesthetic allergy have been rapidly relieved, the inflammatory pigmentation post-laser has significantly improved, the skin barrier has been repaired, and the patient satisfaction rate is extremely high. 金因敷® can effectively reduce redness, swelling and pain for post-medical procedures, accelerate wound healing and shorten the recovery time.
Photo
1:
肌顏態
use
case
sharing
by
Professor
Shi
Ge,
Director
of
the
Department
of
Plastic
Surgery
of
the
Sixth
Affiliated
Hospital
of
Sun
Yat-sen
University;
Photo
2:
肌顏態
use
case
sharing
by
Professor
Ge
Lan,
from
The
First
Affiliated
Hospital
of
Army
Medical
University;
Photo
3:
Fibronectin
clinical
trial
results
sharing
by
Professor
Ye
Li,
Head
of
Cosmetics
Testing
Center
at
Dermatology
Hospital
of
Southern
Medical
University;
Photo
4:
Mr.
Du
Wei,
CEO
of
Cosmetics
News
&
Cosmetics
Business
Online,
analyzes
cosmetics
industry
development
trends
6、The
signing
ceremony
reflects
the
market
potential
Mr. Zhao Zhigang, CEO of Uni-Bio Science Group, emphasized: ” We have always adhered to the standards of biopharmaceuticals in creating skin care products. The release of GeneQueens and 金因敷 is an important milestone in building the “Drugs, Medical device and Aesthetics” strategy and creating a full-cycle skin care solution, aiming to meet consumers’ increasingly refined skin health needs. “
Photo:
Mr.
Zhao
Zhigang,
CEO
of
Uni-Bio
Science
Group,
addressing
the
launch
event.
Furthermore,
Ms.
Liu
Yihua,
President
of
Global
Cosmetics
Group,
attended
the
launch
as
an
important
guest.
Uni-Bio
Science
Group
and
Global
Cosmetics
Group
have
jointly
established
a
medical
research
co-creation
biological
platform.
Utilizing
gene-editing
biosynthesis
technology,
the
platform
has
launched
Skbrella
FN
–
a
highly
bioactive
recombinant
human
fibronectin
known
as
“皮優理”.
The launch also witnessed a grand strategic signing ceremony. The Group has achieved in-depth cooperation with many well-known medical aesthetics chain institutions and well-known agents. This signing is not only a high recognition of the quality and market potential of GeneQueens and 金因敷®, but also a key step for the Group to accelerate commercialization and expand channels. Through strong alliances with leading channel partners, the Group will reach the core consumers and ensure the rapid release of huge commercial value.
Photo:
Group
photo
of
the
strategic
signing
ceremony
The
successful
holding
of
this
launch
not
only
marks
a
crucial
step
for
the
Group
in
medical
aesthetics
and
medical
devices,
but
also
demonstrates
the
Group’s
in-depth
layout
and
forward-looking
vision
in
the
“Drugs,
Medical
device
and
Aesthetics”
strategy.
In
the
future,
the
Group
will
continue
to
be
guided
by
technology
and
oriented
towards
clinical
value,
accelerate
product
innovation
and
technological
upgrading,
constantly
enrich
pipeline,
and
meet
the
growing
market
demands.
Hashtag: #UniBioScienceGroup
The issuer is solely responsible for the content of this announcement.
Support InfoStride News' Credible Journalism: Only credible journalism can guarantee a fair, accountable and transparent society, including democracy and government. It involves a lot of efforts and money. We need your support. Click here to Donate